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Meinolf Suttorp,1 Isaac Yaniv,2 Kirk R. Schultz3Chronic myeloid leukemia (CML) is a relatively rare hematopoietic malignancy in the pediatric and adolescent
population. This makes it difficult to perform clinic trials that can define the best therapeutic option when
considering the impact of tyrosine kinase inhibitors (TKIs) versus the established approach of allogeneic
hematopoietic cell transplantation (HCT). With the relatively low toxicity of TKIs, there are little data
regarding when HCTor long-term TKI therapy is a better option. There are even less data regarding the
duration of TKI treatment in the pediatric CML in chronic phase (CML-CP) patients who may receive
over 60 years of therapy. As children and adolescent are treated for longer times with TKIs, it has become
clear that toxicities may make long-term TKI therapy less attractive compared to allogeneic HCT. HCT has
the long-term complications of growth failure, infertility, chronic graft-versus-host disease (GVHD), meta-
bolic syndrome, and secondary malignancies, whereas prolonged TKIs may cause growth failure, hepatic,
and cardiac complications. Moreover, HCT is a potentially curative intervention, whereas TKI is not curative,
requiring prolonged exposure. In this article, we discuss the relative merit of the 2 therapeutic approaches
and recommend that all children and adolescents with CML-CP should initially be treated with imatinib and
maintained with TKI therapy indefinitely if there is a good response. We recommend that allogeneic HCT
with an HLA-identical sibling donor or closely matched unrelated donor be considered for patients with
treatment failure or recurrence after receiving salvage second-generation TKI treatment. We also conclude
that randomized international trials are urgently needed to evaluate the best therapies for pediatric CML.
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Chronic myeloid leukemia (CML) is a rare hemato-
poietic malignancy representing only 3% of pediatric
and adolescent leukemias [1,2] and 2% of all CMLs.
Because only 110 to 120 pediatric and adolescent CML
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is difficult to perform clinic trials that can define the
best therapeutic option when considering the impact
of tyrosine kinase inhibitors (TKIs) versus the
established approach of allogeneic hematopoietic cell
transplantation (HCT). As TKIs appear to have a
relatively low toxicity profile, it is attractive to consider
this a better option for all situation compared to
allogeneic HCT. However, there are little data to guide
the pediatric oncologist regarding duration of TKIs in
the young patient when it may mean over 60 years of
TKI therapy for a young child affected with CML in
chronic phase (CML-CP). As children and adolescent
are treated for longer times with TKIs, it has become
clear that TKI-related toxicities may make long-term
TKI therapy less attractive compared to allogeneic
HCT, and that TKIs are not curative, allowing their
discontinuation at a particular time point. The following
article will present the current data and controversies
associated with TKI versus allogeneic HCT as therapy
for children and adolescents with CML, and hopefully
will help the pediatric oncologist make good decisions
regarding their patients with CML.S115
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FOR CHILDREN ANDADOLESCENTS WITH
CML
Correlations betweenmolecular effects of imatinib
on BCR-ABL and clinical efficacy in CML have been
well established. Today, imatinib has become the
first-line therapy for all phases of CML in adults.
Also, the appropriate management of children with
CML has been changed radically as only a minority
of pediatric patients are treated now by HCT upfront.
Data from adults show that the effect of time between
diagnosis of CML and HCT on overall survival (OS)
may no longer be important under TKI treatment.
However, the issue of how long the treatment
should be continued still remains unsolved. Prognostic
factors applicable in adult CML to identify high-risk
patients at diagnosis, like the Sokal and Hasford scores,
are not established for children. Possibly, as in adults,
the early response to imatinib is a relevant parameter
for judging the aggressiveness of CML [3].
As an optimized therapeutic approach, close moni-
toring of treatment response (CHR: complete hemato-
logic response; CCyR: complete cytogenetic response;
MMolR: major molecular response), short- and long-
term side effects, and prognostic factors is required. In
addition, the treatment benefits of second-line therapies
(HCT, second-generation TKI) must be considered.
Evidence from Pediatric Trials on CML
Because of the low incidence of CML in children,
only a few pediatric studies have evaluated efficacy of
treating this disease with TKI therapy in children and
adolescents. A Children’s Oncology Group phase I
study evaluated 20 patients with CML after interferon
failure and imatinib-induced CHR in all children in
CML-CP and CCyR in 83%. Responses were also
seen in more advanced phases but were not persistent
[4]. Thirty children were enrolled in a phase II trial in
Europe. Entry criteria were advanced phase disease, re-
lapse after HCT, or failure of interferon. In those chil-
dren with CML-CP, imatinib induced a CHR in 80%
and a cytogenetic remission in 12 of 20 CML-CP and
in 2 of 7 CML-AP. No patient in CML-AP or CML-
BC attained a molecular remission, but 6 of 8 had
a CHR [5]. Forty-four children with de novo CML-
CP were enrolled in a French phase IV study. After
a median treatment duration of 16 months, the CHR
rate was 86% and 98% at 3 months and 6 months,
respectively, whereas 62% of patients achieve CCyR
at 12 months. The proportion of MMolR was 34%
at 12 months [6]. Fifty-one patients have been enrolled
in the ongoing German Berlin-Frankfort-Muenster
(BFM) phase IV trial. Comparable to results observed
in the adult patients entering in CML-CP showed that
40 of 42 patients (95%) had achieved CHR at month
3; 26 of 28 (93%) were CCyR at month 12, and 17 of19 (85%) were MMolR at month 18 after starting ima-
tinib [7]. Taken together, pediatric patients in CML-CP
appear to respond to TKI therapy as well as adults.
Whether or not the kinetics of the response rates differ
in younger patients remains to be determined.
Dose of Imatinib
Doses of 260 to 340mg/m2 imatinib in children give
drug exposures similar to the 400-mgdosage recommen-
ded in adults.Therefore, children should receive300mg/
m2 orally once daily (maximum absolute dose 400 mg)
[4]. In adults, doses of imatinib higher than the
standard 400 mg/day result in more rapid attainment
of molecular response but do not result in better
progression-free survival (PFS) rates [7].The recommen-
ded pediatric doses for CML-AP are 400 mg/m2 daily
(maximum absolute dose 600 mg) and for CML-BP
500 mg/m2 daily (maximum absolute dose: 800 mg) [8].
Short- and Long-Term Toxicity of Tyrosine
Kinase Inhibitors
Imatinib short-term toxicity is common, but the ef-
fects are generally mild to moderate and are very man-
ageable. Children primarily have gastrointestinal tract
toxicity [4,8], and imatinib should be taken with meals
dissolved in apple juice (more soluble at low pH) to
minimize nausea. Other common side effects include
diarrhea, skin rash, edema, a mild transaminitis early
in the course of treatment, and cytopenias. Some
patients may experience lethargy and weight gain.
Myalgias/cramps, usually mild to moderate, occur
more frequently at night or with exertion. Bone pain,
may occur in up to 10% of children and tends to fade
with longer therapy. Female teenagers should avoid
conception while taking imatinib, because of a risk for
fetal abnormalities [9]. Studies in vitro and in animals
suggest that imatinib inhibition of ABL in cardiac tissue
may cause cardiac toxicity. Large adult studies found
that cardiac toxicity is very rare; however, this might
be apotential concern for long-termtherapy inchildren.
Studies in adults have suggested that hypophospha-
temia and dysregulated bone remodeling may be a side
effect of TKI treatment (for review, see [11]). Support-
ing these clinical data, chronic exposure to imatinib
causes the femoral length of juvenile mice to be reduced
with premature growth plate closure in adult rats
[12,13]. In prepubertal children, single case reports
have demonstrated significant longitudinal growth
retardation [10,14,15]. In a French trial, 30 children
exhibited a highly significant (P\ .0001) decrease of
body height Z-score with a median of 20.37 over the
first year of imatinib treatment [6]. A prospective analy-
sis of 57 children treated with imatinib in the German
trial demonstrated hyperparathyroidism in 25% of the
cohort, a significant decline in bone resorption markers
in 60%, and elevated osteocalcin levels (marker of bone
Biol Blood Marrow Transplant 17:S115-S122, 2011 S117Progress in Pediatric CMLformation) at the beginning of imatinib therapy, which
subsequently declined during further treatment before
reaching a normal range [16]. Prepubertal patients ap-
pear to be affected more severely, and careful monitor-
ing of longitudinal height as well as bone metabolic
markers shouldbemandatory under imatinib treatment.
The optimal approach to treat children suffering from
this side effect is still undefined. Second-generation
TKIs like dasatinib and nilotinib are expected to have
the same potential for skeletal effects [11].
Definition of Response and Failure
During treatment, the development of imatinib re-
sistance, intolerance, noncompliance, or progression
to advanced-phase disease must be identified in a timely
fashion. With no established specific recommendations
for children, it appears to be advisable to follow the
guidelines for monitoring residual disease in adults as
proposed by the European LeukemiaNet (http://
www.leukemia-net.org) [17]. Examination of blood
count and differential and normalization of spleen and
liver size should indicate hematologic response earlier
than3months from the onset of treatment.CCyR, as in-
dicated by Philadelphia-chromosome negative marrow
cell metaphase, should be achieved after 12 months of
treatment. Concerning quantitative RT-PCR assess-
ment of BCR-ABL transcript levels to determine the
molecular response, it must be stressed that the sensitiv-
ity level for detection of low numbers of transcripts
varies among laboratories. The established Interna-
tional Scale and the development of reference reagents
for testing laboratories to derive conversion factors to
that scale have provided significant advances toward
the standardization of quantitative RT-PCR for BCR-
ABL. A rate of #0.1% is considered as MMolR and
should be achieved within 18months of treatment. Fail-
ure of imatinib primarily comprises resistance or drug
intolerance.Resistance is categorized intoprimary resis-
tance as a lack of efficacy from the beginning of treat-
ment, or secondary (acquired) resistance defined as an
initial response followed by a loss of efficacy with time
(either molecular or cytogenetic). Resistance may be
multifactorial, including BCR-ABL mutations of
the kinase domain interfering with imatinib binding,
BCR-ABL amplification or overexpression, clonal evo-
lution, and decreased imatinib bioavailability or cell ex-
posure. Patients who cannot continue taking imatinib
because of adverse effects are regarded as intolerant. If
imatinib failure is observed, second-generation TKI
may be beneficial [9].
SecondGeneration Tyrosine Kinase Inhibitors in
Pediatrics
In adults, about 50% of those who fail imatinib
because of resistance and a slightly higher proportion
of those who fail because of intolerance will benefitfrom switching to either dasatinib or nilotinib. Two
randomized phase III studies demonstrated that
dasatinib and nilotinib were superior as initial therapy
to imatinib after 1 year of treatment [18,19]. In
children, only limited data are available on second-
generation TKIs for CML. Dasatinib was studied in
a phase I and an ongoing phase II study in relapsed/
refractory Ph1 leukemias resistant/intolerant to imati-
nib [20]. Among 41 evaluable p on a dasatinib dosage of
60 to 80 mg/m2/day, a complete hematologic response
(CHR) of 75% was seen in CML-CP, and a major cy-
togenetic response rate (MCyR) of 88% in CML-CP.
Dasatinib was well tolerated up to a dose level of 120
mg/m2, and treatment-related toxicities were mild to
moderate in severity (more than grade 4) with nausea
and diarrhea most frequent. So far, no pediatric data
are available for nilotinib, and there is an urgent need
for clinical trials similar to that in adults [21,22].
Monitoring and Steering of Therapy
Disease response should be carefully monitored
with standardized RT-PCR in the long term [17].
Before a diagnosis of failure is made possible, adverse
effects of drug interactions must always be excluded.
Determination of blood drug level may be helpful to
identify noncompliance to regular drug intake—a prob-
lemmore frequently observed in teenagers experiencing
side effects. Monitoring will identify cases of optimal
response, which should continue imatinib as long as
the treatment is effective, whereas in cases of failure to
respond, second-generation TKIs and/or HCT should
be considered [8]. A decision to change to either dasati-
nib or nilotinib should be based on the actual knowledge
accumulated with these drugs in pediatric cohorts, and
ideally these children are enrolled on clinical trials.
Occasional patients may develop rapidly progressive
disease. A 1 log-fold increase in the BCR-ABL/ABL
transcript rate is highly suspicious of loss of response.
In this situation, mutation analysis will help to decide
whether it is helpful to increase the dose of imatinib or
change to a second-generation TKI. It must be remem-
bered that survival remains stage dependent and that
both second-line TKIs dasatinib and nilotinib are inef-
fective against mutation T315I BCR-ABL. By this
approach, it is possible to postpone HCT to a point of
time before the disease progresses to hematologic re-
lapse. Concerns that the use of imatinib prior to HCT
might jeopardize OS seem to be unsubstantiated. How-
ever, a transplant in CML-AP is largely unsuccessful.
Can CML Be Cured if Tyrosine Kinase Inhibitors
Are Discontinued?
Durable MMolR is observed in the majority of
CML patients with imatinib treatment after 1 to 2
years. A new challenge for further optimizing the man-
agement of CML is to determine if treatment with
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those 5% to 10% children with sustained undetectable
disease (F. Millot, M. Suttorp; unpublished observa-
tion). In adults, a pilot study was updated recently re-
porting on the first adult patients who discontinued
imatinib for different reasons after having achieved
a complete molecular response lasting .2 years. Half
of the patients relapsed mostly within\6 months after
discontinuation, but molecular remission could be
regained by reinstitution of imatinib. With an impres-
sively long follow-up interval of median 42 months
after discontinuation, the authors confirmed that
CMR can be sustained in the other half of the patients,
particularly in males and in patients with CML with
cytotoxic NK cells in their peripheral blood [23].
Efforts are presently undertaken by the CML Work-
ing Group of the I-BFM Consortium to initiate a col-
laborative ‘‘Stop imatinib’’ trial in which those few 5%
to 10% of pediatric patients with sustained CMolR
should be included. In addition, a trial in patients
having achieved a sustained MMolR will test the effi-
cacy of an interval treatment (1 month on/1 month
off) aiming to minimize long-term side effects of
TKI in not outgrown patients (personal communica-
tion: Eveline de Bont, Groningen, The Netherlands).
Transplantation in Children and Adolescents
with CML: Open-Ended Versus Curative
Therapy
More than 25 years ago, HCT provided proof of
principle that CML could be cured by eradicating the
malignant clone. To this day, an allogeneic HCT using
marrow, peripheral blood stem cell, or cord blood
donor sources remains the only known treatment avail-
able to cure patients with CML.
HCT Studies on Adult CML
In the last decade, TKI therapy has changed the role
and frequency of HCT for CML in the adult population
has been dramatically reduced [24]. According to data
from the EBMT Chronic Leukemia Working Party,
mortality following matched sibling donor transplant
for CML in adults has decreased substantially. Patients
in first CML-CP, with an EBMT risk score of 0-2, who
received transplants from a matched sibling donor fol-
lowing a standard conditioning regimen between 2002
and 2005 (n 5 214), had a transplant-related mortality
(TRM) rate of 10%, with a 5-year relapse-free survival
(RFS) of 61% [25]. TheGerman study in adults reported
a 91%3-year survival for patients receiving transplants in
CP, 90%ofwhomachieved amolecularCRwith aTRM
ofonly8%.Survivalwas comparable topatients receiving
imatinib [26]. Goldman et al. [27] recently reported on
the long-term outcomes of a large cohort of CML pa-
tients in CP1 undergoing allogeneic HCT. OS rates
at 15 years were 88% for sibling HCT and 87% forunrelated donor HCT. They concluded that recipients
of allogeneic HCT for CML in first CP who remain in
remission for at least 5 years have favorable subsequent
long-term survival.
HCT Studies on Pediatric CML
Although the clinical course of CML in children
seems to be similar to that of adult patients, children
and adolescents are excellent candidates for HCT.
The outcome of HCT in children with CML is similar
to that of adults, with registry studies suggesting a long-
term OS of approximately 70% [28]. The risk score
developed by the European Group for Blood and
Marrow Transplantation (EBMT) for adult patients
may allow for a valid assessment of transplant risk in
the pediatric population as well [29].
In a registry report from the EBMT, the OS at 3
years for children transplanted in first chronic phase
(CP1) from sibling donors or unrelated donors was
75%, and 65%, respectively. However, TRM was
high: 20% in transplants from matched siblings and
31% for recipients of unrelated donor transplants.
Outcome for patients who received transplants in ad-
vanced stage was significantly worse [30].
The prospective CML-pediatric I trial, running
from 1995 to 2004, aimed to transplant children with
CML in first CP from an HLA-matched family donor
within 6 months and from an unrelated donor within
12 months after diagnosis, after initial treatment with
hydroxyurea 6 interferon alpha (IFN-a) [31]. This ap-
proach resulted in an excellent 5-year event-free survival
(EFS) of 87% 6 11% in the group grafted from HLA-
identical family donors (n 5 41). In contrast, those
who were transplanted from an HLA-matched unre-
lated donor had a 5-year EFS of only 52% 6 9% (n 5
71), and those who were grafted from an HLA-
mismatched unrelated donor had a 5-year EFS of
45% 6 16% (n 5 36). Those patients who were trans-
planted in first CP within 6 months from an HLA-
fully matched donor (n 5 144) had a 5-year EFS of
74% 6 9%. This trial was stopped because of poor
patient accrual once imatinib had been fully licensed,
as pediatricians recommend this new drug as initial
treatment. Similarly, a French study reported OS and
PFS of children transplanted in first chronic phase of
73% and 27%, respectively, for those who received
transplants for advanced phase disease. TRMaccounted
for more than 90% of the deaths, and the single most
frequent cause of death was GVHD [32].
Immune Mechanisms That Impact on the
Efficacy of HCT
HCT is the treatment of choice for patients who
have progressed beyond CP1. Transplantation is also
recommended for patients with the T315I mutation,
those who fail to achieve a CyR, or those in cytogenetic
Biol Blood Marrow Transplant 17:S115-S122, 2011 S119Progress in Pediatric CMLrelapse at 12 months from diagnosis. In accelerated
phase and blast crisis, the use of any donor available
should be considered [33]. A role for a natural killer
(NK)-mediated anti-CMLresponse afterHLA identical
sibling HCT through stimulatory KIRs present in the
donor, has been recently demonstrated [34]. HCT fol-
lowing reduced-intensity conditioning (RIC) has been
shown to be feasible inCML.However, only a few pedi-
atric reports have been published to date [35-37]. RIC
transplants should theoretically decrease early TRM
and long-term conditioning-related side effects, by
avoiding radiation and reducing chemotherapy doses.
Posttransplantation therapy for residual disease, in-
cluding withdrawal of immune suppression, donor lym-
phocyte infusion (DLI), and the use of TKIs, are highly
effective in CML [38,39]. Imatinib or a second-
generationTKI shouldbeused if the relapseoccurs early
after transplant, precluding aggressive immunotherapy
use and/or if the child has active GVHD.
Transplant-Related Toxicity Compared to TKI
Toxicity
The price for ‘‘cure’’ by TKI includes life-long
medication and the consistent use of contraception,
whereas the estimated long-term financial cost for
the TKI treatment of an adolescent is US$1.9 million
compared to about US$250,000 for allogeneic HCT.
In countries with limited resources, the cost of a RIC
transplant from a matched family donor is comparable
to 180 days of TKI therapy and should be considered,
especially for the pediatric age group [40,41].
Myeloablative HCT is not only associated with
acute short-term toxicities but also long-term complica-
tions such as chronic GVHD (cGVHD), growth retar-
dation, infertility, metabolic syndrome, organ toxicity,
and second malignancies. RIC HCT is associated with
reduced TRM, use of fewer blood products, reduced
incidence of infection, and shorter hospitalization.
However, reduction in long-term complications still
remains to be proven.
A major concern regarding protracted TKI ther-
apy is reduced compliance in adolescent patients due,
in part, to side effects such as weight gain, abdominal
cramps, diarrhea, and fatigue; these may lead to
a higher incidence of disease recurrence than that
observed in adults. Some studies suggest that TKI
therapy is less effective in the general community
than in clinical trials, a factor more relevant for the
generally less-compliant adolescent population [42].
Compliance is an issue in post HCT management of
adolescents, as well, especially those with cGVHD
and could be similar to life-long TKI treatment.
The Role of TKIs in Transplantation
Lee et al. [43] have shown that treatment with im-
atinib prior to HCT, provided that patients remain inCP at the time of transplant may be associated with
benefits. In a recent study from Japan, retrospectively
reviewed the outcomes of unrelated donor HCT in
125 children with CML. The probabilities of 5-year
OS and leukemia-free survival (LFS) were 59.3% and
55.5%, respectively. Of the 17 patients treated with
imatinib, 15 (88%) achieved MCyR at the time of
bone marrow transplant (BMT), and this group had
an excellent 5-year OS of 81.9%. Transplants appears
to be most effective in this setting of minimal residual
disease (MRD), and TKI therapy may be most useful
given before HCT [44]. The role of TKIs post-HCT
except to treat disease progression is not known.
Imatinib, dasatinib, and nilotinib all may have im-
munosuppressive effects. Imatinib has efficacy in the
treatment of cGVHD [21,22]. In murine models,
dasatinib inhibits tumor necrosis factor alpha (TNF-
a) and interleukin (IL)-6 production by macrophages
after TLR4 stimulation by LPS [45]. This may explain
the development of hemorrhagic colitis as a side effect
in some patients treated with dasatinib [46]. Dasatinib
can inhibit development of antigen specific CD81 and
CD41T cell responses potentially negatively affecting
its efficacy [47]. In a phase II clinical study of 46 adults
with Ph1 ALL, lymphocytosis secondary to dasatinib
correlated with a superior survival. Thus, dasatinib
may induce immune reactivity associated with good
clinical responses.
International collaborative studies are needed to
evaluate the role of HCT for pediatric CML in the
TKI era. Recently, the IBFM HCT group has opened
a study to reduce TRM (better HLA-typing, reduced
conditioning), avoid late effects (infertility, cGVHD),
and prevent hematologic relapse in children and
adolescents with CML by using both improved post-
transplant surveillance and posttransplant therapy
including DLIs and TKIs for residual disease. Donors
maybe amatched siblingdonor, or a 10of 10, 9 of 10un-
related adult donor, or unrelated cord blood. Monthly
molecular monitoring is performed. Intervention for
detected residual disease during the first year posttrans-
plant uses or when GVHD is present is based on TKI
therapy, whereas beyond 1 year with no GVHD, DLI
is employed. This study will hopefully provide better
evidence-based data to determine the best therapeutic
options for children and adolescents with CML.SUMMARY
In summary, the relative role of HCT versus
prolonged TKIs is very uncertain in the pediatric
and adolescent populations. The long-term effects of
prolonged TKI usage appears to be lower than that
seenwithHCT, although onlyHCTcan achieve a per-
manent remission. Any recommendation in children
and adolescents is difficult to defend because of the
Table 1. Response Assessment, Warnings, Monitoring Intervals, and Interventions for CML Patients Treated with Imatinib and after SCT (see [16])
Criteria for Response Assessment
Time Point* Insufficient Imatinib Response Imatinib Failure Warnings
Monitoring During TKI Therapy:
At diagnosis — — High-risk disease according to Sokal/Hasford risk score
Not first chronic phase Add. cytogenetic abnormalities in Ph+ cells (Del 9q+)
At 3 months Less than complete hematology response No hematologic response (stable disease or disease progression) Any new cytogentic abnormality in Ph+ or Ph2 cells
At 6 months Less than partial cytogenetic response (Ph+ >35%) No cytogenetic response (Ph+ >95%) Any new cytogenetic abnormality in Ph+ or Ph2 cells
At 12 months No complete cytogenetic response (Ph+ >95%) No major cytogenetic response (Ph+ >35%) Any new cytogenetic abnormality in Ph+ or Ph2 cells
At 18 months Less than major molecular response (no 3 log reduction) No complete cytogenetic response Any new cytogenetic abnormality in Ph+ or Ph2 cells
At any time Loss of response Disease progression Any new cytogenetic abnormality in Ph+ or Ph2 cells
Mutation? Mutation?
Intervention: SCT might be considered, depending on EBMT risk score at time of warning, insufficient response, or failure.
Monitoring* post-SCT:
Analysis of bone marrow aspirates by real-time quantitative RT-PCR at +1, +2, +3, +6, +9, +12 months after SCT; increase the assay frequency as needed.
Definition of low-risk patient:1) Reduction of BCR-ABL mRNA levels by at least 2 log from baseline at 1 month post-SCT and continuous decline thereafter following SCT.
2) Achievement of MMolR (ratio abl/bcr-abl #0.1%) and maintenance of this stable BCR-ABL transcript level post-SCTor continuous decline thereafter following SCT.
3) Development of aGVHD grade II-IV or extensive cGVHD and Ph+ chromosome negative and stable or decreasing BCR-ABL transcript levels after SCT.
4) CMolR (RT-PCR negative) after SCT.
Intervention: No intervention for low-risk patients.
Definition of high-risk patient:
Not qualifying for any criteria of the low-risk group.
Intervention: Based on individual decisions including withdrawal of immunosuppression, escalating donor lymphocyte infusions, and imatinib mesylate.
SCT indicates stem cell transplantation; GVHD, graft-versus-host disease.
*During the first 2 years, monitoring should occur every 3 months. If a major molecular response (#0.1%) is achieved, the monitoring interval may be prolonged. However, there are no pediatric data in support of this
practice, and until further pediatric data are available, we recommend that peripheral blood be monitored for BCR-ABL every 3 months indefinitely.
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Biol Blood Marrow Transplant 17:S115-S122, 2011 S121Progress in Pediatric CMLlack of available clinical data. Based on the adult data
and what little is known in children, a reasonable ap-
proach appears to be initial treatment with imatinib
in children and adolescents with CML-CP, with
a change to a second-generation TKI if there is an
incomplete response or recurrence after an initial
response. At the time of a change to the second-
generation TKI, an allogeneic HCT from either
a matched sibling or closely matched unrelated donor
should be implemented. Monitoring recommenda-
tions of BCR-ABL for CML on TKI therapy or after
HCT can at this time only be extrapolated from adult
data with the caveat that these populations should be
more closely monitored until additional data are ob-
tained (Table 1). The long-term effects of TKI usage
lasting for a number of decades represent a very big un-
known factor as pediatric oncologists consider the
most appropriate treatment for their patients with
CML. We also conclude that randomized interna-
tional trials are urgently needed to evaluate the best
therapies for pediatric CML.ACKNOWLEDGMENTS
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